The estimated Net Worth of Capital Fund Iii Cooperatie... is at least $49 Million dollars as of 24 July 2018. Capital Cooperatie owns over 133,333 units of Replimune Inc stock worth over $48,961,426 and over the last 6 years Capital sold REPL stock worth over $0.
Capital has made over 1 trades of the Replimune Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 133,333 units of REPL stock worth $1,999,995 on 24 July 2018.
The largest trade Capital's ever made was buying 133,333 units of Replimune Inc stock on 24 July 2018 worth over $1,999,995. On average, Capital trades about 133,333 units every 0 days since 2018. As of 24 July 2018 Capital still owns at least 4,721,449 units of Replimune Inc stock.
You can see the complete history of Capital Cooperatie stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is Gooimeer 2-35, 1411 DC Naarden, Netherlands.
Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves... und Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: